1. Filipits M, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent prognostics information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18)6012-20.
  2. Buus R, et al. Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. 2016;108(11):djw149.
  3. Sestak I, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol. 2018 Feb 15 [Epub ahead of print].
  4. Amin, M et al (Eds.) AJCC Cancer Staging Manual, 8th Ed. New York: Springer; 2017.
  5. Filipits M, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent prognostics information to conventional clinical risk factors [supplementary materials]. Clin Cancer Res. 2011;17(18)6012-20.
  6. Data on file. Myriad Genetics, Inc.
  7. Dubsky P, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013;24(3):640-647
  8. Dubsky P, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer [supplementary materials]. Ann Oncol. 2013;24(3):640-647.
  9. Dubsky P, et al. The EndoPredict score provides prognostic information on late distant metastasis in ER+/HER2- breast cancer patients. Br J Cancer 2013;109(12):2959-2964.
  10. Brase J, et al. From high-throughput microarray-based screening to clinical application: the development of a second generation multigene test for breast cancer prognosis. Microarrays (Basel) 2013;2(3):243-264.
  11. Denkert C, et al. Decentral gene expression analysis for ER+/HER2- cancer prognosis: results of a proficiency testing program for the EndoPredict assay. Virchows Arch. 2012;460(3):251-259.
  12. Jatoi I, et al. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011;29(17)2301-2304.